Daniel Brown, a seasoned first-chair patent trial lawyer, represents pharmaceutical and life sciences companies in patent litigation and other existential disputes, as well as advising on complex cross-disciplinary strategy.
Daniel leverages his chemical engineering background and extensive pharmaceutical IP litigation experience to help clients navigate matters involving patent protection, Food and Drug Administration (FDA) regulation, antitrust and competition, inter partes reexamination proceedings, trade secrets, business and licensing transactions and disputes, due diligence, and investigations. He guides clients on:
He delivers strategy and counseling from a business-focused perspective, coordinating FDA, litigation, and commercial strategy. Daniel connects clients to resources across Latham’s integrated global platform to maximize value, particularly across the FDA Regulatory, Antitrust & Competition, and Government Contracts Practices.
In more than 25 years of experience, Daniel has litigated successfully more than 50 Hatch-Waxman patent cases that resulted in either favorable judgments after trial or in favorable settlements.
Daniel's litigations have involved many prominent pharmaceutical products, such as:
Intellectual Property Litigation partners recognized for brand-side pharmaceutical trial prowess.
Trial skills and victories across IP venues earn recognition.